discuss value I'd our very like QX aspirational both strategy, today you, highlights, Thank creation. execution and the Amol. our much and vision to
for COVID-XX. call Accelerator what previous then in pivot. plus And call COVID-XX continue open the the update China near-term on just going big close beyond we've which we're neuro, will focusing then a CAC and Amol today, a in webcast pivot going for the I'll that navigating call. defined COVID, discussion the financial we we're discuss of is Q&A focus up our then stands provide it in to further to While and
slide on X, our evolve put Biomarkers, disease. neuro acceleration the in we've seen added just we've and XXX. another in slide it So a rapidly. and it's very as a publications see a to to It our we're important you've infectious of This continuing beyond shows so part past. is very eight with to starting are business areas now some total
You well can see, our call neuro drug this to strong do as Accelerator we've we as of now. XXX and studies infectious trials of total very a category and them continue in QX a lot disease and we'll had
XX% We're if year you'll had an XX% onetime in exclude Uman you we And to world our And growth place XXX the for you trial some to QX if the despite the on that base basis now for XX%. see last exclude actually you confronting acquisition. We've the Novartis of instruments. is instruments overall and other drug continued issues installed and order the plus large MS. organic up could was that right see COVID for
important impaired COVID-XX month this are North our has impact, The throughput, in really of overhauling primarily part pretty also -- is our despite reliable third HD-X excluding pretty XX% clinical because slide XX% quarter been in we've installed America. feel On our base from moving the is event. being to run. HD-X. minimal has much the plus this as see onetime. highly was exciting X, more prepared eyes that of much that more was you'll a been for the in which It's clinic we QX just that that in HD-X growth lot a And well of And trials the
also have XXX seen facility. from to We -- resilience have protect place. to we a and some facility moved people We in in plan the we steps outside our employees took the early
now So, great months. outside XXX over I the remain two XXX have last the we had facility. we've mean just the two And in -- really facility, performance quarters
some just not do Sorry COVID. our stellar of clock worldwide working XX/X. last We month around around team enough about despite the say the concerns
well in our sensitivity we on, safety to Once early we started technologies repositioned exquisite start we COVID with virus. hand allowing had helped which the
has the our really lot been that months over well actually system as that's response measuring to COVID virus remarkable immune response. the work last drugs impair Precision the so Health X.X as around up Powering to try coming data And to waking of worldwide the the a to networks out
Because which in storm to cytokine some is great it so leads cases, and this that to leads response pneumonia death.
as system this going pretty now that research into system to it's you're our to for So moving carefully quarter. we're learn planning well the with serology monitor testing important only to use we're innate the launch as immune to continue
predicted continue technology prevents it it many already just our the their down in on were them part allow And where Accelerator have important with doing which expand occurred to HD-X using the would install. they to HD-X to HD-X labs. growth validation and our runs we already is crossover of of this while on HD-X from initial were Our based use customers the QX which customers an to we
we So, that expansion. planned already for
anywhere they been laboratories running oncology running many we've shifted XX% have COVID that the great times as some have been labs, we've heard for think, was COVID have it customers labs. numbers into So have of so from is our close. their did into to closed the seen neurology Many were there over trials XX% and labs labs throughout laboratories. those I what from we industry And that converted
utility growth really to technology Simoa really And times. and during have is we're We to had see worldwide is engage in we that, and our these even you collaborators despite crossover. the if we consumables. the that good continued in see the neurology. our see you about growth and onetime And flow continuing, in doubled services reinforce in this to But can HD-X to was in can XX% PPH our our COVID move to HD-X nearly quarter. publication activity which other lab the revenue continuing products, consumables instruments Particularly and you
almost Now, in XX%. representing quarter, this past
conversion, to expansion. And another the basis it gross would margins had HD-X XXX for If continue point weren't to improve. HD-X over we
about the at with of the as COVID. past But growth to effect spend now position, the we to on time we lot this Slide not do that. issues CROs a some I build can maintain We're to that. we're our seeing. pharma, position, Asia and onetime XX-XX It's that, we're that you but academia. And dealing continuing the X, just illustrates overall continues continuing meaningful of look out percentages a despite neurology to expand split demographics. our won't And between dominate, as see of slide. given are
testing. cerebral testing to really the slide used be So evolving or spinal procedures getting that and pathology on in invasive to biopsies late invasive get operations that answers we've in as to to past noninvasive like, answers for fluids, X, shown we're disease early taps spinal and and an late the required
into pointed today when there's see high-content on have you go our biomarkers But more you and technologies out crossed And as XXX over with today's magnitude protein for below, technology. on high-concentration clinic. X,XXX IVD that side into Simoa a can the RSU X, we roll we're in there's in proteins. what can we are out left slide further to almost see today the think to the can clinical markets measure there's you probably the aspirations we start proteins RUO, only move to as relevance, have that we've opportunities providing but insights it Primarily,
many turn right-hand COVID. And actually storm, create cytokine of for being those of on many of pneumonia side, COVID. dimensions you the the important these Many biomarkers. And the cytokines that and and lethal very for see into are the measured can these are
critical of the hot that deployed are And the patients world and excited our really COVID, support ICU around these, to we're why, it's zones. so the in many technologies monitor getting to that's
used. drug using us million to lower us biomarkers, efficacy with led X you've And get great to you opportunity to much catalysts, showcase of for an are basically attract approved, as engage drugs to before the before. much can of side. higher a see can revenue cohorts no approval the is on actually allowed being you the of what's efficacy that's It X reimbursement achieve left-hand the if seen and earlier has Slide to in multiple drug growth that the biomarkers diseases companies shows symptoms probability risk XXXX. biomarkers a dosing. approval enabled $XX and because probability slide after We regulatory this using from go Phase higher many And
As you that we're can QX, continuing see growth. in
our years very successfully change that, We level for infectious a reentering overall category HIV core of opportunity next a market with But we now now, is were some research globally. doing will we're because are this infectious pXX. structural think We of into be globally with disease there it, expansion once disease. the five
engaged now in that lot to of of studies a PPH will our So into work lead and and ecosystem this is publications we're landscape. well migrating lot a
as quarter regulatory. to exciting. is I it which out well, projects very looking month see exciting. think stays starting Again, one low also or is just Accelerator And this this cohorts we're COVID already came COVID, still pretty for which at
we penetration. early think have the and a and RUO strong in very very do we we with profile think I do we're economic
in has in across lot and our immunoglobulins, proven different months We all work a three the IgM do management of very across have IgG, great himself as area of Walt as antigens. of done well IgA last who and serology a showcasing over two four the technology the David founder
data on quantitative is IgG. for compelling technology fidelity Some high pretty shown and being even
first. LDT. we And on of at from that this starting we we're very landscape to would some what year. towards is exploring in We move interesting see working aspiration into the diagnostics as CDx moving right-hand in said We the said now we're least side, across. at start But opportunities, the even serology the neurology companion the beginning of
it through And us that explore, years but for partnerships, IgG to possibilities it there enter with landscape might that if as then into going ultimately, continue to to probably take being several well. would landscape to into is the get be serology we current felt we're
with optionality. fidelity of are so great think we in out being do again, a now looking left-hand to opens creation a blood test fidelity high RUO lot high the we high-value at So, sensitivity COVID-XX test side. we've precise rolling added optionality. serology up And And our that on
make markets will that for data some serology we into if an would IVD from evolve sense consider, basis. actual So clinical
IVD and exploring to partnerships continue high We we're do those. see potential continue to going
that and do our the with work are already of companies of own below. lot some shown technology And a doing us
X% side as mode it's area. the still talked where Luminex, light use in left But the of On competitors we're of to blue oncology our and SP-X XX% than and penetrated neurology. slide on we've in larger than penetrated. the started many XX, neurology that that oncology our to focus in we plan primarily But in execution less we're into landscape MSD, HD-X evolve biotech was less
were those going oncology, assets we to found products and those but the of into expand lot to So adaptable a we've COVID-XX quite pandemic. are
now we've have oncology redeployed and labs many our so labs of anyway. many COVID-XX become And assets those of
serology, in test the So exquisite important negatives. positives minimize it's in the redeployed and be and in And almost know sensitivity every world to almost important of entry the teach false negatives. positives can to way us reductions it's across of that attributes false and area false about and earlier that's create very the COVID-XX, to how we an for
particularly right-hand HD-X side, continued as those still the and HD-X the of have neurofilament of side. disease right-hand are SP-X as landscape well we infectious exploring the SR-X for aspirations as light MS but the on now for in So as well the evolution we on
RUO adaptive helping modulation just slide is in well three as systems trying to immune innate launch, able with as it's So our pronged hoping drugs immune to we COVID-XX, serology shows and now and attack we're drug lethal mentioned try our to the and cytokine storm targets line product adaptive before with this and with to the effective immune measure, for companies predict sometime in tests that the be drugs. and QX. trying to to And looking the pivot, get XX, both intervene
and the important And technologies. we'll evolve for treatments. an be And continue so area vaccine see them for we vaccines plasma development to our drugs also convalescence
ways for now strong for COVID the population immunity is population they can times we'll Accelerator in We're innate to The area work. catch We build during we these research think of China. And population us, to only built figure a sooner China will a actually to adaptive. And how coming accelerated and so and be back of pretty studies serology important or this interruptions. Accelerator. out and to the think start seeing very market the the on either has services get world interest also for of a opportunity out is even also caught full We wave around RUO strong very believe opportunity. we've that this have use of our we wanted has COVID back year, who
You -- we having see of lot in all actually enable tap the that been of are out we'll different sample a from and commercialization call our large with an the those that a all network around the can around the world a sets on in rapid can really hot into. world slide XX, PPH a banks a base technologies helping RUO from We've the basis. it, PP collaborators roll webinars live zones. investors the There's installed very
in to for serology next want was we out three And another probably pretty you test to kits. compelling. and plan one several have the we'll the If as RUO accessible one, weeks, ago listen the it that's roll we weeks had
we've So we're interferon is, immune franchise it this cytokine Then can serum slide the area already were we and at with as antibody our an next some area. as vaccines storm into as, as important, on going and disease side where but point, well on There markers. on see right-hand exploring adaptively. in of be RUO We're in XX, severity landscape. convalescent do development immunity what moving pro-inflammatory number only for is response we doing innate, this EUAs passport one, oncology think that to are this as moving we based you production well mentioned drug been
and established of both panels we storm and immune all drug This the predictive for that slide showcases XX, the the measuring just innate the product system for further different have in lines interactions. cytokine
on potentially blood have early Slide as launch it the working componentry key infection RUO some see QX almost and reducing orthogonal providing our see being IgG earlier XX into infection just sensitivity right some quantitative opportunities describes Starting high determination like we'd positives markets now from we're and test, panel. QX to serology for that it. We very and the of these can And what in with of COVID-XX negatives. in specificity, we false itself. for immune the much potentially even as volume
false And the we know today that there's a in lot positives of serology landscape.
of detection false result know swabs, as nasal missed. get also lot hard as viral much viruses onto could these It's We as and a XX% of negatives in landscape. be there's to the a many
build of So having immunity to some orthogonal early after is the of a understanding great tests. these way go
and XXX utilized around per HD-Xs -- got does as know around fact instrument measure the as day X,XXX can the technology HD-Xs we've And Our over in you if world. as HD-X right tests many clock. per the
HD-X and and around HD-X rollout banks, enhancing to probably that our opportunity. helping IgG accelerate HD-X quantitative test. on we launch hopefully value world, an still be in the HD-X Our the RUO would QX Sample something deploy customers, further, hope we as initial mentioned would to to
The slides two talk the next several number just adaptive. about
lot a IgM, when can those historic right-hand of and of have creating to the a they a which see viruses they someone lead that tests. of They there's positives, important are lot lot don't, serology on of that's side of and a IgG a viruses, thinking could lot tricking trait. measure lot immunity false You there's an historic today's
dilute can in sensitivity, see of several curves can and next look different a having at see these with and particularly we slides interested you samples thousand-fold, earlier by these the we're it exquisite as what we So is IgG can this we in, quantitation.
ultra the false So that from we viral think key eliminate the detection. negatives is for sensitive even
productive test and world. in out so utilize sensitivity. the our see help being to And that And to ultra slide roll try highly to on quantitative summary RUO and sensitive corner right XX, is top specific, we and the want we
products pricks answer and drawing anyway need then of eliminate sensitivity the finger to potentially dilute point, We because its blood the and going getting at to saliva exquisite some matrix effects. also are from explore and to
So would network XX already group. month similar commercial year. half offerings second gets XX, probably to for PPH but some on in this. really QX nice a and and COVID the by with COVID, from did know for of momentum We've infectious that of be were had our slide we headwinds the drive end QX is some this the of QX meetings the product We disease at April QX webinar intent build to to trying out is for roll obviously and some
further China, companies different ability that retrospective see Accelerator innate particularly are to in for been is to think to And to technology the one COVID, Accelerator into neuro. product already trials the our where these move shut that we have already a might to continue important enhance down which interacting immunity for together see together in with appropriately. be running help we're that by sales we further you position commercial linking demonstrate to the we year modulating all cytokines is try can and ability. trials, and of actually help end to the starting to see continuing our in up footprint, our has an can hope that we're out Accelerator China build to look organization signed one at how also and And I for is Accelerator it drug
kits been services SP-X. that's the that And COVID. Slide Once now bead based, XX into we It's evolving HD-X we panel high can you there's that we're is the see and the products XX-plex but we planar sell then the just based again, and then used And which two in SR-X. oncology, that shows the sell. cytokine provide. various a
-- XX our from Slide approved XXX% it lot last repeat down It just the by a for by that's up want utilize after cohorts. use of that come companies all of earlier modulating efficacy our lot really shows drug it. probability a the of to can years: technology X and and you toxicity, these modulating is growth further to momentum of the And past. being slide approval, drug Phase by the three increase creates where seeing if our a a has from
Accelerator is serology that which and engage CROs the there's looking And and strong serology interact RUO that tests, those of and like X to with places have to We like tests. also rules-based other it, have pharma now with to out that at our Phase run deployed and you vaccines we technologies, LabCorp Frankly could able many be see medicine. in ourselves going we're important to are number very we'd if our for are to those own facilities If trying of those XXX others lab. now we capability. X, our be roll customers Quest CRO in partners X projects drugs
And or those taste, smell, of lot it even neuro continues loss loss examples, CNS of believe the and a not, are explore there's COVID of to where FDA there's functionality.
our So at we run neuronal neuronal lot implications damage, we starting way now showcase and looking even another of have just COVID a which think customers is to of to technologies. death Nf-L,
the building base what this in a are further research Slide validation technology companies technology shows deploying others our and XX just strong now installed biotechnologies, can pharmaceuticals, institutions, and do. for CROs, and either that all
focused of just still the we we there's already post-COVID, endpoints. trials think a utilized are very publications. opportunity this as XX Phase now them to Nf-L. technology FDA know with drugs our on MS X a just like MS have surrogate for We meeting There's is to several Slide There's strong secondary disease-progression trials. would very in saying have a opportunity we'd year. like to get avalanche of that And an that
the trying getting some be monitoring slide are due for Originally, look our approved we in start delays go there to evidence. sorry, starts to drugs organization to can all we as using but just Nf-L actively least at MS with but first commercial at trials and our Nf-L. progression talk Nf-L way aren't find clinical -- that be how using wanted disease half, Nf-L it is for currently the technology where and which which approved, using are And Nf-L total it where this the opportunities to year, to the now about COVID then to this companies ones shows of are
you feel low -- we very we're have still so see we penetration. And a can
point So, neuronal these opportunities our each get salesforce is kind there's approvals. becoming to from using educated pipelines quarter as we more out can to use benefit where tools of that Nf-L for
XX, point as of that they to show it that a used it trials trial. that approval have end shows a in our then key have and others and the one drug slide surrogate Phase in Novartis they're June technologies secondary hoping This as used well for Biogen. X Roche in
we're continuing to this. just evolve So,
their dying, someday patients could working. think know allow between figure years to because two today's as We everyone up and right MRI Nf-L sooner wheelchair long Nf-L a versus being waiting standing a level. it versus two, And with drug will to whether should is the get be drug as half the measuring out by on difference in a
and is Nf-L data. within Testing tell think three whether via our in compelling can the publications drug death Nf-L some reducing and blood is slowing pretty test. down non-invasive neuronal months, there's stopping and evidence you we This
we previously. And trials the talked that this big is about two
analytical groups what study left the which attempts And the in to age an same an Switzerland, It's healthy. age is think show getting currently different analytical major then validity level to if XX normative seven patients the trial be Nf-L you're from different going average on which there's should sites validity. the at healthy we around Nf-L proves our world. a XX On with results
suggest our Alzheimer's other to validity Parkinson's or occurring brain be there's damage whether or of neuronal clinical some anything that's concussions think we from or damage and would neurodegeneration support some physical disease that the further MS claims. to some above So, that it going
to strong given utilization year still more can we we it's for full technology. like see going we as installed think potential But -- as which wanted be think for update the a to slide still our move. is in still end, by COVID XX% year remarkable well pretty HD-Xs we XX% we the So, get
We're develop of into high-resolution we're that response. year revenue sure, $X the opportunity. see we second but million this potential infectious for into we for putting disease. continuing think to from pivot And We infectious have can't to the JOLT $X half say the real does immune million COVID-XX the for disease potential that that
standpoint, strategic still a something focused we're on. partnership is the From IVD
Our continue to plan to look forward also opportunistic M&A.
We sheet. have We right that this trauma a of a know balance lot now. gone strong through industry has
so any to what our And be we call there we'll to to want support -- ways perpetration. opportunistic strategy accelerate
can for gross margin. goals You see our
on moment, taking based that in think we're end and have we trying can but out still to year, the revenue For just for and HD-Xs the the off that XX we place total sort by the year full line SR-Xs XX SP-Xs.
lot headcount right And still to our in pilots investments great the now slashing look seeing of R&D our continue and XXXx for continue to advance for a work increase sensitivity we not moment.
even We feel ever chance is think showcase remains to is than we've now before. and that don't having in bullish way in the offensive our the we probably got grow growth long-term technology now to into COVID. second opportunity half we we company faster more a damage like any a strong want our very to opportunity we're think And this
you. So, Amol, I'd slide there and like to to over this stop turn
